Wall Street analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post sales of $9.17 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with estimates ranging from $6.77 million to $15.40 million. Intellia Therapeutics reported sales of $5.63 million in the same quarter last year, which suggests a positive year over year growth rate of 62.9%. The business is expected to issue its next quarterly earnings results on Tuesday, March 13th.

According to Zacks, analysts expect that Intellia Therapeutics will report full year sales of $9.17 million for the current financial year, with estimates ranging from $26.21 million to $34.80 million. For the next year, analysts forecast that the business will post sales of $39.43 million per share, with estimates ranging from $23.70 million to $54.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The firm had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. During the same period last year, the company earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 49.0% on a year-over-year basis.

Several research analysts have recently issued reports on the company. Barclays reissued a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. TheStreet cut Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, December 14th. BidaskClub cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, ValuEngine cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. Intellia Therapeutics presently has an average rating of “Hold” and an average price target of $30.17.

In related news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nessan Bermingham sold 111,500 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $20.34, for a total value of $2,267,910.00. Following the transaction, the chief executive officer now directly owns 696,000 shares of the company’s stock, valued at approximately $14,156,640. The disclosure for this sale can be found here. Insiders have sold 1,971,283 shares of company stock valued at $37,137,161 in the last ninety days. Company insiders own 12.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. boosted its position in shares of Intellia Therapeutics by 58.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 42,674 shares of the company’s stock valued at $683,000 after purchasing an additional 15,771 shares during the period. Rhumbline Advisers acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at $275,000. State of Wisconsin Investment Board acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at $160,000. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at $101,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Intellia Therapeutics by 73.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock valued at $876,000 after purchasing an additional 23,126 shares during the period. 48.95% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics (NASDAQ:NTLA) traded up $0.53 during trading hours on Friday, hitting $21.45. The stock had a trading volume of 513,690 shares, compared to its average volume of 826,203. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $33.34. The company has a market capitalization of $754.91, a PE ratio of -13.75 and a beta of 1.73.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/13/intellia-therapeutics-inc-ntla-expected-to-post-quarterly-sales-of-9-17-million-2.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.